Sonoma Pharmaceuticals and its partner, the MicroSafe Group DMCC, announce that the Australian Therapeutic Goods Administration has approved extended claims for Nanocyn Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma’s patented Microcyn technology. Nanocyn was previously approved by the TGA and entered into The Australian Register of Therapeutic Goods with a 15 second kill time against SARS-CoV-2, and a 30 second kill time against Norovirus, Influenza A, and bacteria, such as Staphylococcus aureus, E. coli, Pseudomonas aeruginosa. The TGA has now also approved Nanocyn for use against Candida auris and Clostritium Difficile in ten minutes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNOA: